Celiac Disease - Pipeline Review, H1 2018

  • ID: 4479910
  • Drug Pipelines
  • 83 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Calypso Biotech SA
  • F. Hoffmann-La Roche Ltd
  • IB Pharmaceuticals Inc
  • ImmusanT Inc
  • Intrexon Corp
  • MORE
Celiac Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2018, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 10 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Calypso Biotech SA
  • F. Hoffmann-La Roche Ltd
  • IB Pharmaceuticals Inc
  • ImmusanT Inc
  • Intrexon Corp
  • MORE
Introduction

Report Coverage

Celiac Disease - Overview

Celiac Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Celiac Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Celiac Disease - Companies Involved in Therapeutics Development

Amgen Inc

Calypso Biotech SA

F. Hoffmann-La Roche Ltd

IB Pharmaceuticals Inc

ImmusanT Inc

Intrexon Corp

Selecta Biosciences Inc

Takeda Pharmaceutical Co Ltd

Topas Therapeutics GmbH

Zedira GmbH

Celiac Disease - Drug Profiles

AMG-714 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVX-176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNZ-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CALY-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERW-1041E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kuma-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larazotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

latiglutenase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nexvax-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nexvax-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Celiac Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZED-1227 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZED-754 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Celiac Disease - Dormant Projects

Celiac Disease - Product Development Milestones

Featured News & Press Releases

Jan 08, 2018 : Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA

Jan 04, 2018 : ImmusanT Provides Year-End Update and Outlines Goals for 2018

Nov 28, 2017: ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies

Oct 31, 2017: ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease

Oct 25, 2017: ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data at United European Gastroenterology Week

Oct 12, 2017: ImmusanT to Present New Nexvax2 Dosing Data at United European Gastroenterology Week

Sep 13, 2017: Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis

Sep 11, 2017: ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax

Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science

Aug 21, 2017: Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA - a Novel Treatment for Celiac Disease

Jun 06, 2017: Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention

May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients

May 08, 2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach

May 02, 2017: ImmunogenX to Make Highlighted Presentations at DDW 2

May 02, 2017: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Celiac Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Celiac Disease - Pipeline by Amgen Inc, H1 2018

Celiac Disease - Pipeline by Calypso Biotech SA, H1 2018

Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Celiac Disease - Pipeline by IB Pharmaceuticals Inc, H1 2018

Celiac Disease - Pipeline by ImmusanT Inc, H1 2018

Celiac Disease - Pipeline by Intrexon Corp, H1 2018

Celiac Disease - Pipeline by Selecta Biosciences Inc, H1 2018

Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Celiac Disease - Pipeline by Topas Therapeutics GmbH, H1 2018

Celiac Disease - Pipeline by Zedira GmbH, H1 2018

Celiac Disease - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Celiac Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Calypso Biotech SA
  • F. Hoffmann-La Roche Ltd
  • IB Pharmaceuticals Inc
  • ImmusanT Inc
  • Intrexon Corp
  • Selecta Biosciences Inc
  • Takeda Pharmaceutical Co Ltd
  • Topas Therapeutics GmbH
  • Zedira GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll